Glimy M 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle cells. The synergistic action of these two agents provides effective glycemic control in patients inadequately managed by diet and exercise alone or monotherapy. Glimy M 1 Tablet PR is typically prescribed to improve glycemic parameters such as fasting plasma glucose and HbA1c levels. It is important to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypoglycemia, particularly due to Glimepiride. Dose adjustments should be individualized based on patient response and tolerability. This medication should be used under medical supervision with regular monitoring of blood glucose and periodic assessment of renal and hepatic function.